+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode of Administration, Mechanism of Action, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode of Administration, Mechanism of Action, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode of Administration, Mechanism of Action, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532841
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Heart Failure Therapeutics Market is projected to reach USD 31.69 Billion in 2026. It is expected to continue growing at a CAGR of 10.94%, reaching USD 60.23 Billion by 2032.

Heart failure therapeutics remain central to cardiovascular care because heart failure affects more than 64 million people worldwide, while cardiovascular diseases cause an estimated 17.9 million deaths each year, according to the World Health Organization. The heart failure treatment landscape is shifting from episodic symptom control toward guideline-directed medical therapy that lowers mortality, reduces hospitalization, improves functional status, and slows disease progression across reduced, mildly reduced, and preserved ejection fraction.

Demand for evidence-based heart failure drugs is reinforced by aging populations, diabetes, obesity, hypertension, chronic kidney disease, and improved survival after myocardial infarction. Clinicians are increasingly using angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, diuretics, iron repletion, and device-enabled care in integrated pathways designed to improve outcomes and support long-term disease management.

Transformative Shifts in the Heart Failure Landscape

The heart failure therapeutics landscape is being reshaped by the rapid adoption of four-pillar treatment for heart failure with reduced ejection fraction, wider use of SGLT2 inhibitors across ejection-fraction categories, and earlier initiation of combination therapy after diagnosis or hospital discharge. Major guidelines from the AHA, ACC, HFSA, and ESC emphasize faster optimization of evidence-based medicines rather than slow sequential escalation, reflecting clinical trial evidence that timely treatment reduces cardiovascular death and heart failure hospitalization.

Commercial strategy is also changing. Payers increasingly evaluate heart failure therapies by their ability to reduce hospital admissions, improve quality of life, support outpatient management, and lower avoidable acute-care use. At the same time, patent expirations, generic availability, fixed-dose combinations, remote patient monitoring, and multidisciplinary care models are changing access, pricing, adherence, and differentiation across the heart failure drug market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler in heart failure therapeutics rather than a standalone treatment. Validated AI tools are being applied to electrocardiogram interpretation, echocardiography workflows, risk stratification, patient identification, medication adherence support, and prediction of clinical decompensation using electronic health records, imaging, laboratory results, wearable devices, and remote monitoring data.

The cumulative impact is strongest where AI improves earlier diagnosis, therapy titration, clinical trial recruitment, population health management, and pharmacovigilance. However, adoption depends on transparent validation, demographic fairness, cybersecurity, clinician oversight, and regulatory alignment. For drug developers and healthcare decision-makers, AI-enabled real-world evidence can strengthen market access dossiers, identify underdiagnosed patients, and support selection of patients most likely to benefit from specific heart failure therapies.

Key Regional Insights Across Heart Failure Therapeutics

Asia-Pacific is a highly dynamic heart failure therapeutics region due to large aging populations, rising diabetes prevalence, urbanization, and expanding cardiology infrastructure across China, India, Japan, Australia, and South Korea. North America remains a leading innovation and adoption hub, supported by AHA/ACC/HFSA guideline implementation, specialist heart failure programs, clinical trial density, advanced diagnostics, and comparatively strong reimbursement for branded therapies, outpatient care models, and digital health integration.

Latin America shows increasing demand for heart failure treatment but faces uneven access to advanced medicines, diagnostics, and specialist services, with Brazil and Mexico acting as key regional anchors. Europe benefits from ESC-led standardization, national health technology assessment systems, broad use of evidence-based therapy, and structured pharmacovigilance, although cost-effectiveness scrutiny is significant. The Middle East is expanding cardiovascular investment as diabetes, hypertension, and obesity burden rises, while Africa remains underpenetrated, with affordability, diagnosis rates, workforce capacity, and supply continuity shaping therapeutic uptake.

Key Group Insights for Strategic Market Positioning

ASEAN markets are gaining relevance as hospital networks expand and governments strengthen noncommunicable disease programs, though access to newer heart failure medicines varies by reimbursement, public procurement, and urban-rural capacity. The GCC is strategically important because high rates of diabetes, hypertension, obesity, and chronic kidney disease create sustained demand for cardiometabolic and heart failure care, supported by healthcare modernization programs, specialty centers, and investment in digital health infrastructure.

The European Union provides regulatory scale, pharmacovigilance infrastructure, and health technology assessment-driven pricing discipline, making clinical value and budget impact central to access. BRICS countries combine large patient pools with rising domestic manufacturing, expanding insurance coverage, and cost-sensitive procurement, making affordability, local evidence, and supply reliability essential. G7 markets lead in clinical innovation, premium therapy adoption, and real-world evidence generation. NATO members, while not a healthcare bloc, overlap with major high-income markets where supply-chain resilience, essential medicines security, and health-system readiness are increasingly strategic priorities.

Key Country Insights in Major Heart Failure Markets

The United States is the most commercially influential heart failure therapeutics market, supported by high disease burden, advanced specialty care, broad clinical trial participation, and rapid incorporation of guideline-directed medical therapy; Canada follows similar clinical standards with stronger centralized cost-effectiveness review and provincial reimbursement influence. Mexico and Brazil are important Latin American markets where public access, private insurance penetration, local procurement, and specialist availability determine uptake of advanced heart failure medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature cardiology systems with pricing oversight, national reimbursement rules, and guideline-based care pathways, while Russia presents a large patient base with access, procurement, and geopolitical constraints. China and India drive Asia-Pacific patient volume, supported by expanding diagnosis, domestic manufacturing, hospital capacity, and policy attention to chronic disease management. Japan, Australia, and South Korea are advanced markets with strong regulatory standards, aging populations, high-quality cardiovascular care, and growing interest in integrated drug-device-digital heart failure management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and programs that demonstrably reduce hospitalization, cardiovascular mortality, symptom burden, and total cost of care. Portfolio strategies should align with guideline-directed medical therapy, support rapid titration, and address common comorbidities such as chronic kidney disease, diabetes, iron deficiency, hypertension, atrial fibrillation, and obesity.

Manufacturers should expand real-world evidence, pursue inclusive clinical trials, strengthen payer-ready economic models, and invest in patient support that improves treatment persistence and adherence. Regional strategies must balance premium innovation with affordability through tiered pricing, local partnerships, supply security, physician education, and care pathway support for primary care and cardiology teams. AI-enabled identification, remote monitoring integration, decentralized follow-up, and outcomes-based contracting can further improve differentiation in heart failure therapeutics.

Research Methodology

The research methodology is built on secondary research from verified public and scientific sources, including global health agencies, cardiology guidelines, regulatory labels, peer-reviewed clinical trials, health technology assessment frameworks, epidemiology databases, and disease burden publications. Priority was given to evidence from the World Health Organization, AHA/ACC/HFSA, ESC, national regulatory authorities, and landmark randomized heart failure trials evaluating mortality, hospitalization, safety, and quality-of-life outcomes.

Insights were triangulated across disease burden, treatment standards, regulatory status, reimbursement dynamics, clinical adoption, access barriers, comorbidity patterns, and regional healthcare capacity. The analysis avoids unsupported market-size claims and focuses on evidence-backed therapeutic, geographic, and strategic signals relevant to heart failure drug developers, investors, payers, providers, and healthcare decision-makers.

Conclusion

Heart failure therapeutics are entering a more outcomes-driven phase defined by earlier diagnosis, faster initiation of combination therapy, broader SGLT2 inhibitor use, stronger comorbidity management, and deeper integration of digital and AI-enabled care. The competitive landscape rewards therapies that improve survival, reduce hospitalization, simplify care pathways, enhance adherence, and prove value in real-world heart failure populations.

Growth opportunities are strongest where clinical innovation is paired with access strategy and implementation support. Organizations that combine robust evidence, regional affordability, payer engagement, supply reliability, and technology-enabled patient management will be best positioned to meet rising demand across mature and emerging heart failure therapeutics markets.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Heart Failure Therapeutics Market, by Drug Class
7.1. ACE Inhibitors
7.2. Angiotensin II Receptor Blockers
7.3. Beta Blockers
7.4. Diuretics
7.5. Mineralocorticoid Receptor Antagonists
7.6. SGLT2 Inhibitors
8. Heart Failure Therapeutics Market, by Heart Failure Type
8.1. Preserved Ejection Fraction
8.2. Reduced Ejection Fraction
8.3. Heart Failure with Mildly Reduced EF
9. Heart Failure Therapeutics Market, by Mode Of Administration
9.1. Intravenous
9.2. Oral
10. Heart Failure Therapeutics Market, by Mechanism of Action
10.1. Neurohormonal Modulation
10.2. Vasodilation
10.3. Positive Inotropy
10.4. Metabolic Modulation
11. Heart Failure Therapeutics Market, by End User
11.1. Clinics
11.2. Home Care Settings
11.3. Hospitals
12. Heart Failure Therapeutics Market, by Distribution Channel
12.1. Offline
12.1.1. Hospital Pharmacies
12.1.2. Retail Pharmacies
12.2. Online
13. Asia-Pacific Heart Failure Therapeutics Market
14. North America Heart Failure Therapeutics Market
15. Latin America Heart Failure Therapeutics Market
16. Europe Heart Failure Therapeutics Market
17. Middle East Heart Failure Therapeutics Market
18. Africa Heart Failure Therapeutics Market
19. ASEAN Heart Failure Therapeutics Market
20. GCC Heart Failure Therapeutics Market
21. European Union Heart Failure Therapeutics Market
22. BRICS Heart Failure Therapeutics Market
23. G7 Heart Failure Therapeutics Market
24. NATO Heart Failure Therapeutics Market
25. United States Heart Failure Therapeutics Market
26. China Heart Failure Therapeutics Market
27. Germany Heart Failure Therapeutics Market
28. United Kingdom Heart Failure Therapeutics Market
29. India Heart Failure Therapeutics Market
30. Canada Heart Failure Therapeutics Market
31. France Heart Failure Therapeutics Market
32. Mexico Heart Failure Therapeutics Market
33. Brazil Heart Failure Therapeutics Market
34. Australia Heart Failure Therapeutics Market
35. Japan Heart Failure Therapeutics Market
36. South Korea Heart Failure Therapeutics Market
37. Italy Heart Failure Therapeutics Market
38. Russia Heart Failure Therapeutics Market
39. Spain Heart Failure Therapeutics Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Abbott Laboratories
41.2. Abiomed, Inc.
41.3. Amgen Inc.
41.4. AstraZeneca PLC
41.5. Bayer AG
41.6. BioCardia, Inc.
41.7. Boehringer Ingelheim International GmbH
41.8. Boston Scientific Corporation
41.9. Bristol-Myers Squibb Company
41.10. CVRx, Inc.
41.11. Cytokinetics, Inc.
41.12. Edwards Lifesciences Corporation
41.13. Eli Lilly and Company
41.14. GlaxoSmithKline plc
41.15. Hikma Pharmaceuticals PLC
41.16. Johnson & Johnson Services, Inc.
41.17. Les Laboratoires Servier
41.18. Medtronic plc
41.19. Merck & Co., Inc.
41.20. Novartis AG
41.21. Orion Corporation
41.22. Pfizer Inc.
41.23. PhaseBio Pharmaceuticals, Inc.
41.24. Renova Therapeutics, Inc.
41.25. Sanofi S.A.
41.26. Takeda Pharmaceutical Company Limited
List of Figures
FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ACE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ACE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ACE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DIURETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DIURETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DIURETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL VASODILATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL VASODILATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL VASODILATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL METABOLIC MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL METABOLIC MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL METABOLIC MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 83. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 85. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 87. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 120. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 121. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 123. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 125. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 128. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 130. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 131. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 132. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 133. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 134. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 136. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 137. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 138. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 139. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 141. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 142. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 152. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 155. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 157. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 160. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 161. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 162. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 163. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 165. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 168. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 169. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 170. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 171. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 172. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 173. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 174. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 175. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 177. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 184. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 185. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 186. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 187. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 189. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 192. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 193. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 195. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 197. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 200. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 208. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 211. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 213. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 214. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 216. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 217. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 218. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 219. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 220. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 221. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 222. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 223. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 224. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 227. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 228. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 229. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 231. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 232. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 233. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 234. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 235. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 237. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 240. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 241. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 242. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 243. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 244. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 245. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 246. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 248. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 249. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 250. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 251. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 252. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 253. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 255. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 256. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 257. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 258. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 259. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 260. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 261. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 263. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 264. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 265. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 267. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 268. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 269. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 270. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 271. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 272. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 273. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 274. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 275. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 276. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 277. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 278. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 279. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 280. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 281. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 282. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 283. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 284. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 285. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 286. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 287. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
TABLE 288. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 289. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 290. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
TABLE 291. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 292. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 293. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 295. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Heart Failure Therapeutics market report include:
  • Abbott Laboratories
  • Abiomed, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCardia, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CVRx, Inc.
  • Cytokinetics, Inc.
  • Edwards Lifesciences Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Les Laboratoires Servier
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Renova Therapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Table Information

Report AttributeDetails
No. of Pages193
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 31.69 Billion
Forecasted Market Value ( USD ) by 2032 $ 60.23 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Heart Failure Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Congestive Heart Failure Treatment Device Market by Device Type, Therapeutic Modality, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Congestive Heart Failure Treatment Device Market by Device Type, Therapeutic Modality, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
a-Acetyldigitoxin Market - Global Forecast 2026-2032 - Product Image

a-Acetyldigitoxin Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Cardiovascular Clinical Trials - Global Strategic Business Report - Product Image

Cardiovascular Clinical Trials - Global Strategic Business Report

  • Report
  • 393 Pages
  • Global
From
Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report - Product Image

Dilated Cardiomyopathy Therapeutics - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Heart Failure Drug Market

The Heart Failure Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat a variety of heart-related conditions. Heart Failure Drugs are used to treat heart failure, a condition in which the heart is unable to pump enough blood to meet the body's needs. These drugs can help reduce symptoms, improve quality of life, and reduce the risk of death. Commonly used Heart Failure Drugs include ACE inhibitors, beta blockers, diuretics, and angiotensin receptor blockers. These drugs work by reducing the workload on the heart, improving blood flow, and reducing fluid buildup in the body. Some companies in the Heart Failure Drug market include Pfizer, Novartis, Merck, Sanofi, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.